King's College London

Research portal

Cytoreductive nephrectomy in the era of targeted therapies: a review

Research output: Contribution to journalArticle

Nisha Pindoria, Nicholas Raison, Gideon Blecher, Rick Catterwell, Prokar Dasgupta

Original languageEnglish
Pages (from-to)320–328
Number of pages9
JournalBJU International
Volume120
Issue number3
DOIs
Publication statusE-pub ahead of print - 2 May 2017

Documents

  • Cytoreductive nephrectomy in the era_PINDORIA_Publishedonline2May2017_GREEN AAM

    Cytoreductive_therapy_in_the_era_PINDORIA_Publishedonline2May2017_GREEN_AAM.pdf, 211 KB, application/pdf

    2/05/2018

    Accepted author manuscript

    Other

    This is the peer reviewed version of the following article, published in BJU International, v. 120 issue 3, September 2017, which has been published in final form at http://dx.doi.org/10.1111/bju.13860. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

King's Authors

Abstract

In the pre-targeted therapy era, palliative cytoreductive nephrectomy combined with cytokine immunotherapy was the standard treatment protocol for the management of metastatic renal cell carcinoma. The introduction of targeted therapies has improved response rates, median survival and overall prognosis when compared to immunotherapy. The role of cytoreductive nephrectomy in providing an independent survival advantage when used alongside immunotherapy has been demonstrated by two randomised controlled trials. However, with the new shift in improved treatment outcomes from cytokine immunotherapy to targeted therapies, the continuing role of cytoreductive nephrectomy as a viable surgical treatment method remains controversial.

Download statistics

No data available

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454